BTLS.BR Biotalys NV
- Market cap
- EUR 73.4M
- P/E
- -
- P/B
- 4.99x
- ROE
- -122.2%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BTLS.BR undervalued?
Graham numberThe Graham number of Biotalys NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biotalys NV fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-122.2%), below 10%.
ROA 0/1
Return on assets (-80.9%) is below the industry median (6.0%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (-6.0%) is above the industry median (-37.9%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (21.6%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.9 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (5.0x) is above the industry median (1.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Biotalys NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biotalys NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; B…
Full company profileBiotalys NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biotalys NV annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Operating Income | -9.24M | -13.3M | -18.1M | -22.5M | -20.9M | -13.5M | -15.8M | -18.3M |
| EBITDA | -8.66M | -13.0M | -16.8M | -20.9M | -19.1M | -11.7M | -13.9M | -9.98M |
| Net Income | -7.67M | -10.8M | -16.9M | -22.7M | -20.5M | -13.2M | -15.8M | -18.3M |
| EPS | -0.26 | -0.36 | -0.56 | -0.74 | -0.65 | -0.40 | -0.42 | -0.47 |
| Balance Sheet | ||||||||
| Total Assets | 27.5M | 36.3M | 70.3M | 49.5M | 36.6M | 36.7M | 19.7M | 22.6M |
| Total Liabilities | 6.44M | 10.6M | 11.4M | 11.4M | 11.0M | 9.14M | 7.63M | 7.63M |
| Shareholders' Equity | 21.1M | 25.6M | 58.9M | 38.1M | 25.6M | 27.6M | 12.1M | 15.0M |
| Cash & Short-term Investments | 23.4M | 25.2M | 56.1M | 34.1M | 21.6M | 22.6M | 8.04M | 14.0M |
| Total Debt | 1.19M | 5.22M | 7.22M | 6.50M | 6.07M | 4.85M | 3.78M | 3.24M |
| Cash Flow | ||||||||
| Operating Cash Flow | -8.22M | -9.53M | -16.8M | -20.1M | -18.3M | -12.7M | -13.7M | -15.2M |
| Capital Expenditure | 645K | 3.93M | 1.33M | 707K | 455K | 138K | 182K | 36.0K |
| Free Cash Flow | -8.87M | -13.5M | -18.1M | -20.8M | -18.7M | -12.8M | -13.9M | -15.3M |
| Ratios | ||||||||
| ROE | -36.4% | -41.9% | -28.7% | -59.6% | -80.2% | -47.8% | -130.2% | -122.2% |
| ROA | -27.9% | -29.6% | -24.1% | -45.9% | -56.1% | -35.9% | -79.9% | -80.9% |
| Debt to Equity | 0.06x | 0.20x | 0.12x | 0.17x | 0.24x | 0.18x | 0.31x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biotalys NV dividends
Biotalys NV has not paid dividends in the last 7 fiscal years.
Who owns Biotalys NV
- Insiders 27.44%
- Institutions 17.69%
- Public & others 54.87%
- Shares outstanding 45.4M
- Free float 25.6M
Biotalys NV company profile
- Company name
- Biotalys NV
- Ticker
- BTLS.BR
- ISIN
- BE0974386188
- Exchange
- Euronext Brussels
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 37
- Fiscal year end
- December
- Address
- Buchtenstraat 11, Ghent, Belgium, 9051
- Phone
- 32 9 274 54 00
- Website
- biotalys.com
About Biotalys NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; BIOFUN-4 targeting oomycetes in fruits and vegetables; BIOFUN-8 targeting altenaria in fruits, vegetables, and specialty crops; and BioIns-2 targeting key insect pests. The company was formerly known as Agrosavfe NV and changed its name to Biotalys NV in December 2019. Biotalys NV was incorporated in 2013 and is headquartered in Ghent, Belgium.
Biotalys NV management
3- Dr. Carlo BouttonCEO & Chief Scientific Officer
- Mr. Luc Van FraeyenhovenChief Financial Officer
- Toon MusschootHead of Investor Relations & Communication